Our results, which revealed substantial tracer uptake in several entities and no significant difference in tumor uptake after different lines of therapy, support the notion that CXCR4-directed RLT could represent a viable option for extensively pre-treated patients in solid tumor entities. The gene discussed is CXCR4; the disease is neoplasm.